Table 2.

Indications and contraindications of drugs in the treatment of COVID-19.

Drugs	Indications	Contraindications
Antiviral drugs
Paxlovid	Paxlovid is a combination therapy for the treatment of mild to moderate COVID-19 in patients who are at high risk of progression to severe COVID-19.	Paxlovid is contraindicated in patients with a known hypersensitivity to any component of the medication.
Molnupiravir	Molnupiravir is an antiviral medication for the treatment of COVID-19 in adults who are at risk of progression to severe COVID-19 and/or hospitalization.	Molnupiravir is contraindicated in patients with a known hypersensitivity to any component of the medication. Also, Molnupiravir is not authorized for use in patients aged <18 years; not authorized for initiation of treatment in patients requiring hospitalization owing to COVID-19; not authorized for use for >5 consecutive days Not authorized for preexposure or postexposure prophylaxis of COVID-19.
Remdesivir	Remdesivir is an antiviral medication for the treatment of COVID-19 in adults and pediatric patients (12 years of age and older and weighing at least 40 kg) requiring hospitalization.	Remdesivir is contraindicated in patients with a known hypersensitivity to any component of the medication.
Monoclonal antibodies
Bamlanivimab and etesevimab	Bamlanivimab and etesevimab are monoclonal antibodies indicated for the treatment of mild to moderate COVID-19 in patients who are at high risk of progression to severe COVID-19 and/or hospitalization.	There are no known contraindications for Bamlanivimab and etesevimab.
Casirivimab and imdevimab	Casirivimab and imdevimab are monoclonal antibodies indicated for the treatment of mild to moderate COVID-19 in patients who are at high risk of progression to severe COVID-19 and/or hospitalization.	There are no known contraindications for Casirivimab and imdevimab.
IL-6R inhibitor/Immune Modulators
Tocilizumab	Tocilizumab is an immunosuppressive medication used to treat moderate to severe rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, and cytokine release syndrome caused by CAR T-cell therapy or COVID-19.	Tocilizumab is contraindicated in patients with a known hypersensitivity to any component of the medication. For all immunosuppressive treatments, secondary bacterial and fungal infections should be closely monitored.
Sarilumab	Sarilumab is an immunosuppressive medication used to treat moderate to severe rheumatoid arthritis and cytokine release syndrome caused by CAR T-cell therapy or COVID-19.	Sarilumab is contraindicated in patients with a known hypersensitivity to any component of the medication.
Baricitinib	Baricitinib is an immunosuppressive medication used to treat moderate to severe rheumatoid arthritis and COVID-19 in combination with remdesivir.	Baricitinib is contraindicated in patients with a known hypersensitivity to any component of the medication.
Ruxolitinib	Ruxolitinib is an immunosuppressive medication used to treat certain types of bone marrow disorders and cytokine release syndrome caused by CAR T-cell therapy or COVID-19.	Ruxolitinib is contraindicated in patients with a known hypersensitivity to any component of the medication.
Tofacitinib	Tofacitinib is an immunosuppressive medication used to treat moderate to severe rheumatoid arthritis and cytokine release syndrome caused by CAR T-cell therapy or COVID-19.	Tofacitinib is contraindicated in patients with a known hypersensitivity to any component of the medication.
Systemic corticosteroids
Dexamethasone	Dexamethasone is a corticosteroid medication used to treat a variety of inflammatory and autoimmune conditions, as well as to reduce inflammation in certain types of cancer.	Dexamethasone is contraindicated in patients with a known hypersensitivity to any component of the medication. It should also be used with caution in patients with certain infections, such as systemic fungal infections, due to the risk of exacerbating the infection.